Sana Biotechnology Names Brian Piper as New CFO

Sana Biotechnology ( (SANA) ) has issued an update.

On February 17, 2026, Sana Biotechnology appointed Brian Piper as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer, ending CEO Steve Harr’s interim role as acting principal financial officer. Piper, a veteran biotech finance executive with more than 25 years of industry experience, previously held CFO posts at Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, and Aevi Genomic Medicine, and earlier served in senior finance and investor relations roles at Shire Pharmaceuticals.

Under the terms of his offer, Piper will receive a $515,000 base salary, a target annual bonus equal to 40% of salary, and equity awards comprising stock options for 900,000 shares and 200,000 restricted stock units that vest over four years. His compensation package includes severance protections and eligibility under Sana’s change-in-control severance plan, underscoring the company’s effort to strengthen its financial leadership as it advances key clinical programs in type 1 diabetes and B‑cell–related diseases and navigates upcoming value inflection points for investors and patients.

The most recent analyst rating on (SANA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.

Spark’s Take on SANA Stock

According to Spark, TipRanks’ AI Analyst, SANA is a Neutral.

Overall score is held back primarily by weak financial fundamentals typical of a development-stage biotech (no revenue, large losses, and continued cash burn with higher leverage). Technicals are moderately supportive with the stock trading above major moving averages and mild positive momentum, while valuation remains challenged due to negative earnings. A positive corporate update on diabetes cell-therapy progress provides an additional tailwind but does not offset the funding and execution risk implied by current financials.

To see Spark’s full report on SANA stock, click here.

More about Sana Biotechnology

Sana Biotechnology, Inc., listed on Nasdaq as SANA, is a cell and gene therapy company focused on creating and delivering engineered cells as medicines to repair and control genes and replace missing or damaged cells. The company is developing programs in areas such as type 1 diabetes and in vivo CAR T therapies, with operations in Seattle, Cambridge, and South San Francisco and an aim to make its treatments broadly accessible.

Average Trading Volume: 3,613,344

Technical Sentiment Signal: Sell

Current Market Cap: $1.03B

Find detailed analytics on SANA stock on TipRanks’ Stock Analysis page.